EUROPEAN PERSPECTIVES IN PERSONALISED MEDICINE

12-13 MAY 2011
Square-Brussels Meeting Centre

CONFERENCE PROGRAMME
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:00</td>
<td>Registration and welcome coffee</td>
<td>ENTRANCE HALL &amp; FOYERS</td>
</tr>
<tr>
<td>09:00-10:30</td>
<td>Official conference opening and keynote session</td>
<td>COPPER HALL</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>Coffee break</td>
<td>SILVER &amp; MAGRITTE FOYERS</td>
</tr>
<tr>
<td>11:00-13:00</td>
<td>Session 1: R&amp;D - the basics</td>
<td>COPPER HALL</td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>Lunch break</td>
<td>SILVER &amp; MAGRITTE FOYERS</td>
</tr>
<tr>
<td>14:30-16:00</td>
<td>Session 2: Biomarkers in personalised medicine</td>
<td>COPPER HALL</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Coffee break</td>
<td>SILVER &amp; MAGRITTE FOYERS</td>
</tr>
<tr>
<td>16:30-18:00</td>
<td>Session 3: The tests in human - clinical aspects and clinical research</td>
<td>SILVER &amp; MAGRITTE FOYERS</td>
</tr>
<tr>
<td>18:00-19:00</td>
<td>Networking cocktail</td>
<td>SILVER &amp; MAGRITTE FOYERS</td>
</tr>
<tr>
<td>07:30-08:30</td>
<td>Registration and welcome coffee</td>
<td>ENTRANCE HALL &amp; FOYERS</td>
</tr>
<tr>
<td>08:30-10:00</td>
<td>Keynote session</td>
<td>COPPER HALL</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee break</td>
<td>SILVER &amp; MAGRITTE FOYERS</td>
</tr>
<tr>
<td>10:30-12:00</td>
<td>Session 4: Towards the market and patients - approval process</td>
<td>COPPER HALL</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Lunch break</td>
<td>SILVER &amp; MAGRITTE FOYERS</td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>Session 5: Uptake in healthcare - post approval process</td>
<td>COPPER HALL</td>
</tr>
<tr>
<td>14:30-14:45</td>
<td>Coffee break</td>
<td>SILVER &amp; MAGRITTE FOYERS</td>
</tr>
<tr>
<td>14:45-16:00</td>
<td>Session 6: In the clinic - practitioner and patient perspectives</td>
<td>COPPER HALL</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Closing Session</td>
<td>COPPER HALL</td>
</tr>
</tbody>
</table>

**THURSDAY 12 MAY**

**FRIDAY 13 MAY**
THURSDAY 12 MAY

09:00-10:30  **Official conference opening and keynote session**

**Speakers**

Máire Geoghegan-Quinn  
Commissioner for Research, Innovation and Science, European Commission

Jonathan Knowles  
Professor of Translational Medicine, Ecole Polytechnique Fédérale de Lausanne, Switzerland and Professor in Personalised Health Care, Finnish Institute for Molecular Medicine, University of Helsinki  
Vice Chairman and Chief Scientific Officer, Caris Life Sciences

Axel Ullrich  
Professor and Director, Department for Molecular Biology, Max Planck Institute of Biochemistry, Germany

**Session Chair**

Ruxandra Draghia-Akli  
Director, Directorate Health, DG Research and Innovation, European Commission
THURSDAY 12 MAY

11:00-13:00  **Session 1: R&D - the basics**

*The role of "omics" research and in vitro and in vivo technologies in the development of personalised medicine – opportunities for clinical utility*

**Speakers**

**Tim Aitman**  
Professor, Clinical and Molecular Genetics, Group Head and Head of Molecular Sciences, Imperial College London, UK

**Mathias Uhlén**  
Professor, Science for Life Laboratory and Albanova University Centre, Swedish Royal Institute of Technology

**Markus Schwaiger**  
Professor and Director of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany

**Panel**

**Alvis Brazma**  
Senior Team Leader, Functional Genomics, European Bioinformatics Institute (EBI), UK

**Hinrich Gronemeyer**  
Research Director, Institute of Genetics, Cellular and Molecular Biology, Strasbourg-Illkirch and French National Institute of Health and Medical Research (INSERM)

**Ivo Gut**  
Director, National Genome Analysis Centre (CNAG), Barcelona, Spain

**Kerstin Lindblad-Toh**  
Professor, Comparative Genomics, Science for Life Laboratory, Uppsala University, Sweden  
Scientific Director of Vertebrate Genome Biology, Broad Institute, USA

**Session Chair**

**Detlef Niese**  
Head External Affairs Global Development, Novartis Pharma
THURSDAY 12 MAY

14:30-16:00 **Session 2: Biomarkers in personalised medicine**

*Taking stock of biomarkers – key challenges in identification, validation and qualification of safety and efficacy biomarkers*

**Speakers**

**Catherine Larue**  
Business Unit Director, Bio-Rad

**Charles Swanton**  
Group leader, Translational Cancer Therapeutics, London Research Institute, Cancer Research UK

**Krishna Prasad**  
Clinical Assessor, Medicines and Healthcare products Regulatory Agency, UK

**Panel**

**Thomas Beyer**  
CEO, cmi-experts and Head of the New Technology working group, Association of Imaging Producers & Equipment Suppliers (AIPES)

**Magnus Ingelman-Sundberg**  
Professor of Molecular Toxicology, Department of Physiology and Pharmacology, Karolinska Institute, Sweden

**Alastair Kent**  
Chairman, European Platform for Patient Organisations, Science and Industry (EPPOSI)

**Andreas Schuppert**  
Director, Applied Sciences, Bayer Technology Services

**Session Chair**

**Romano Danesi**  
Professor, Department of Internal Medicine, University of Pisa, Italy
16:30-18:00  **Session 3: The tests in human - clinical aspects and clinical research**

*Clinical research and clinical trials in the age of personalised medicine – needs and considerations*

**Speakers**

**Anne De Bock**  
Portfolio leader Oncology & Infection, Astrazeneca

**Munir Pirmohamed**  
Professor and Chair of Clinical Pharmacology, University of Liverpool and  
NHS Chair of Pharmacogenetics, UK

**Panel**

**John Danesh**  
Professor, Department of Public Health and Primary Care, Cambridge University, UK

**Jane Kaye**  
Director, Centre for Law, Health and Emerging Technologies, Oxford University, UK

**Denis Lacombe**  
Director, European Organisation for Research and Treatment of Cancer (EORTC)

**Cees Smit**  
Policy advisor, Patients Network for Medical Research and Health (EGAN)

**Anne-Mieke Vandamme**  
Professor, Katholieke Universiteit Leuven and  
Head of Division Clinical and Epidemiological Virology, Rega Institute and University Hospitals, Belgium

**Session Chair**

**Ingrid Klingman**  
Chair of the Board, European Forum for Good Clinical Practice (EFGCP)
FRIDAY 13 MAY

08:30-10:00 **Keynote session**

**Speakers**

**John Dalli**
Commissioner for Health and Consumer Policy, European Commission

**Fabien Calvo**
Deputy Director General and Director of Research, French National Cancer Institute (INCa)

**Elizabeth Ofili**
Associate Dean for Clinical Research, Professor of Medicine, Chief of Cardiology and Director, Clinical Research Centre, Morehouse School of Medicine, Atlanta, USA

**Session Chair**

**Isabel de la Mata**
Principal Adviser with Special interest in Public Health, DG Health and Consumer Policy, European Commission
FRIDAY 13 MAY

10:30-12:00  **Session 4: Towards the market and patients - approval process**

*The regulatory framework and personalised medicine – integrating innovative technologies while ensuring quality and safety for patients*

**Speakers**

**Thomas Metcalfe**  
Head, Science & Technology Incubator, Translational Research Sciences, Roche Pharma  
Chair, Personalised Medicine Taskforce, European Biopharmaceutical Enterprises (EBE)

**Marisa Papaluca-Amati**  
Section Head of Scientific Support and Projects, European Medicines Agency

**Anne Van Nerom**  
Coordinator of the Belgian Competent Authority for in vitro diagnostic medical devices,  
Scientific Institute of Public Health

**Panel**

**Deborah Braun**  
Group leader R&D team in Oncology, bioMérieux

**Ian Cree**  
Director, Translational Oncology Research Centre and Cancer Laboratory, Queen Alexandra Hospital,  
Portsmouth, UK

**Carlo Incerti**  
Senior Vice President, Global Market Access, Genzyme

**Milan Macek**  
Professor, Charles University, Prague, Czech Republic  
President, European Society of Human Genetics

**Session chair**

**Alain Huriez**  
CEO, TcLand Expression  
Chairman, European Association for Personalised Medicine (EPEMED)
13:00-14:30  **Session 5: Uptake in healthcare - post approval process**

*Cost-benefit approaches in personalised medicine – uptake in healthcare systems and incentives for innovation*

**Speakers**

**Richard Bergström**  
Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA)

**Katherine Payne**  
Professor of Health Economics, University of Manchester, UK

**Anna Bucsics**  
Head of Department, Main Association of Austrian Social Insurance Institutions (HVB)

**Panel**

**Angela Brand**  
Professor, Maastricht University and Director, European Centre for Public Health Genomics (ECPHG), Maastricht, the Netherlands

**Finn Børlum Kristensen**  
Director, Centre for Evaluation and HTA, National Board of Health of Denmark and Director of EUnetHTA

**Mirella Marlow**  
Programme Director, UK National Institute for Health and Clinical Excellence

**Clare McGrath**  
Senior Director, HTA Policy, Europe, Pfizer

**Session chair**

**Tim Kievits**  
CEO PamGene  
Chair, Personalised Medicine Taskforce, EuropaBio
Session 6: In the clinic – practitioner and patient perspectives

Implementing personalised medicine, the role of patients and practitioners – availability, awareness, resources and needs

Speakers

David Haerry
Member of the Board of Directors, European AIDS Treatment Group

Matthias Schwab
Professor and Chair of Clinical Pharmacology, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany

Panel

Olga Golubnitschaja
Professor, Department of Radiology, University of Bonn, Germany
Secretary-General, European Association for Predictive, Preventive and Personalised Medicine (EPMA)

John Ionescu
Scientific Director, Special Clinic Neukirchen, Germany
Professor, Danube University Krems, Austria

Damjana Rozman
Professor of Biochemistry and Molecular Biology and Head of the Centre for Functional Genomics and Bio-Chips, University of Ljubljana, Slovenia

Session Chair

Jean-Jacques Cassiman
Professor Emeritus, Katholieke Universiteit Leuven, Belgium
FRIDAY 13 MAY

16.00-16:30  **Closing Session**

*Conclusions – challenges and opportunities in personalised medicine, the short-, medium-, and long-term vision for Europe*

**Speakers**

**Anders Olauson**  
President, European Patients' Forum

**Rudolf Strohmeier**  
Deputy Director General, DG Research and Innovation, European Commission
The process towards personalised medicine, aimed at better predicting, preventing and treating or curing diseases based on a patient’s individual characteristics, is gaining pace in Europe. However, a long term structured approach to foster innovation in this area and to facilitate the rapid uptake of personalised medicine into clinical practice is lacking.

The conference brings together stakeholders involved in all areas of personalised medicine and aims at identifying key challenges where actions are needed at European level to progress research, development and implementation of personalised medicine in health care.

Conference presentations and biographies of all speakers and panellists will be available on www.ec.europa.eu/research/health/events_en.html